International Clinical Trial: Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07852962) titled 'Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Bristol-Myers Squibb

Condition: Healthy Volunteers

Intervention: Drug: BMS-986446

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: February 10, 2027

Target Sample Size: 10

To know more, visit https://clinicaltrials.gov/study/NCT07852962

Publ...